Document:

trhc_Ex4.3

		
			Exhibit 4.3
		

		
			 
		

		
			DESCRIPTION OF THE REGISTRANT’S SECURITIES
		

		
			REGISTERED PURSUANT TO SECTION 12 OF THE
		

		
			SECURITIES EXCHANGE ACT OF 1934
		

		
			 
		

		
			The following summary describes the common stock, par value $0.0001 per share, of Tabula Rasa HealthCare, Inc. (“TRHC,” “we,” “us,” and “our”), which are the only securities of TRHC registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended.
		

		
			 
		

		
			The following description is a summary and does not purport to be complete. It is subject to, and qualified in its entirety by reference to, our amended and restated certificate of incorporation (which we refer to as our “certificate of incorporation”) and our amended and restated bylaws (which we refer to as our “bylaws”), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.3 is a part. The terms of these securities also may be affected by the General Corporation Law of the State of Delaware (which we refer to below as the “DGCL”).
		

		
			Authorized Capital Stock
		

		
			Our authorized capital stock consists of 100,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of undesignated preferred stock, par value $0.0001 per share. 
		

		
			Description of Common Stock
		

		
			Our common stock is entitled to one vote for each share held of record on all matters submitted to a vote of the stockholders, including the election of directors, and does not have cumulative voting rights. Accordingly, the holders of a majority of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election. Subject to preferences that may be applicable to any then outstanding preferred stock, the holders of common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.
		

		
			Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. All of our outstanding shares of common stock are, and the shares of common stock that we may offer pursuant to this prospectus will be, fully paid and nonassessable.
		

		
			Our common stock is not convertible into, or exchangeable for, any other class or series of our capital stock. Holders of our common stock do not have preemptive or other rights to subscribe for or purchase additional securities of ours. The transfer agent and registrar for our common stock is American Stock Transfer & Trust Company, LLC. The transfer agent and registrar's address is 6201 15th Avenue, Brooklyn, NY 11219. Our common stock is listed on The Nasdaq Global Market under the symbol “TRHC.”
		

		
			Description of Preferred Stock
		

		
			Our board of directors is authorized, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any 

		 

qualifications, limitations or restrictions thereon and to increase or decrease the number of shares of any such series, but not below the number of shares of such series then outstanding.
		

		
			Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or impair the liquidation rights of our common stock or otherwise adversely affect the rights of holders of our common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock.
		

		
			ANTI-TAKEOVER EFFECTS OF DELAWARE LAW,
OUR CERTIFICATE OF INCORPORATION AND OUR BYLAWS
		

		
			Provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult to acquire us by means of a tender offer, a proxy contest, open market purchases, removal of incumbent directors and otherwise. These provisions, summarized below, are expected to discourage types of coercive takeover practices and inadequate takeover bids and to encourage persons seeking to acquire control of us to first negotiate with us. We believe that the benefits of increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because negotiation of these proposals could result in an improvement of their terms.
		

		
			Delaware Anti-Takeover Law
		

		
			We are subject to Section 203 of the DGCL (which we refer to as “Section 203”). Section 203 generally prohibits a public Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless:
		

			
	
			
				 ·
			

			
	
			
			prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

			
	
			
				 ·
			

			
	
			
			the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

			
	
			
				 ·
			

			
	
			
			on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 662/3% of the outstanding voting stock which is not owned by the interested stockholder.

		
			Section 203 defines a business combination to include:
		

			
	
			
				 ·
			

			
	
			
			any merger or consolidation involving the corporation and the interested stockholder;

		
			 
		

			
	
			
				 ·
			

			
	
			
			any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;

		
			 
		

			
	
			
				 ·
			

			
	
			
			subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder;

		
			 
		

			
	
			
				 ·
			

			
	
			
			subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; and

		
			 
		

		
			

		 

		

			
	
			
				 ·
			

			
	
			
			the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.

		
			In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.
		

		
			The existence of this provision generally will have an anti-takeover effect for transactions not approved in advance by the board of directors, including discouraging attempts that might result in a premium over the market price for the shares of common stock held by stockholders.
		

		
			Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws
		

		
			Provisions of certificate of incorporation and bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our certificate of incorporation and bylaws:
		

			
	
			
				 ·
			

			
	
			
			permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and privileges as they may designate (including the right to approve an acquisition or other change in our control);

		
			 
		

			
	
			
				 ·
			

			
	
			
			provide that the authorized number of directors may be changed only by resolution of our board of directors;

		
			 
		

			
	
			
				 ·
			

			
	
			
			provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;

		
			 
		

			
	
			
				 ·
			

			
	
			
			divide our board of directors into three classes;

		
			 
		

			
	
			
				 ·
			

			
	
			
			require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;

		
			 
		

			
	
			
				 ·
			

			
	
			
			provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner, and also specify requirements as to the form and content of a stockholder’s notice;

		
			 
		

			
	
			
				 ·
			

			
	
			
			do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); and

		
			 
		

			
	
			
				 ·
			

			
	
			
			provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.

		
			The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 662/3% of our then outstanding capital stock, voting together as a single class.trhc_Ex10.13

		
			Exhibit 10.13
		

		
			LOAN AND SECURITY MODIFICATION AGREEMENT
		

		
			This Loan and Security Modification Agreement (this “Amendment”), is entered into as of December 20, 2019, by and among (i) CAREKINESIS, INC., a Delaware corporation (“CareKinesis”), TABULA RASA HEALTHCARE, INC., a Delaware corporation (“Parent”), CAREVENTIONS, INC., a Delaware corporation (“Careventions”), CAPSTONE PERFORMANCE SYSTEMS, LLC, a Delaware limited liability company (“Capstone”), J. A. ROBERTSON, INC., a California corporation (“Robertson”), MEDLIANCE LLC, an Arizona limited liability company (“Medliance”), CK SOLUTIONS, LLC, a Delaware limited liability company (“CK Solutions”), TRSHC HOLDINGS, LLC, a Delaware limited liability company (“TRSHC”), SINFONIARX, INC., an Arizona corporation (“SinfoniaRX”); TRHC MEC HOLDINGS, LLC, a Delaware limited liability company (“TRHC”), MEDITURE LLC, a Minnesota limited liability company (“Mediture”), ECLUSIVE L.L.C., a Minnesota limited liability company (“eClusive”), COGNIFY, LLC, a Delaware limited liability company (“Cognify”), and DOSEME, LLC, a Delaware limited liability company f/k/a TRHC DM Holdings, LLC (“DoseMe,” and together with Parent, CareKinesis, Careventions, Capstone, Robertson, Medliance, CK Solutions, TRSHC, SinfoniaRX, TRHC, Mediture,  eClusive and Cognify are each referred to herein as a “Borrower”, and collectively, as the “Borrowers”), (ii) the several banks and other financial institutions or entities party hereto (each a “Lender” and, collectively, the “Lenders”), and (iii) WESTERN ALLIANCE BANK, an Arizona corporation (“Bank”), as a Lender and as administrative agent and collateral agent for the Lenders (in such capacities, the “Administrative Agent”).
		

		
			DESCRIPTION OF EXISTING INDEBTEDNESS:  Among other indebtedness which may be owing by the Borrowers to Bank, the Borrowers are indebted to Bank pursuant to, among other documents, an Amended and Restated Loan and Security Agreement, dated September 6, 2017 by and among the Borrowers, the Lenders and the Administrative Agent, as may be amended from time to time (the “Loan and Security Agreement”).  Capitalized terms used without definition herein shall have the meanings assigned to them in the Loan and Security Agreement.
		

		
			The Loan and Security Agreement and any and all other documents executed by the Borrowers in favor of the Lenders and/or the Administrative Agent shall be hereinafter referred to as the “Existing Documents.”
		

		
			DESCRIPTION OF CHANGE IN TERMS.
		

		
			Consent.  Notwithstanding the provisions of Section 7.2 of the Loan and Security Agreement to the contrary, and so long as no other Event of Default has occurred, is continuing, or would result therefrom, the Administrative Agent and the Lenders hereby consent to CareKinesis changing it legal name to TRHC OpCo, Inc.
		

		
			Modification(s) to Loan and Security Agreement:
		

		
			1)Section 6.3 of the Loan and Security Agreement is hereby amended and restated in its entirety as follows:
		

		
			6.3Financial Statements, Reports, Certificates.  Borrowers shall deliver the following to Administrative Agent:   as soon as available, but in any event within thirty (30) days after the last day of each fiscal quarter, an aged listings of accounts receivable and accounts payable by invoice date and a deferred revenue report;  as soon as available, but in any event within thirty (30) days after the last day of each fiscal quarter, a company prepared consolidated and consolidating balance sheet, income statement, and cash flow statement covering Borrowers’ operations during such period, prepared in accordance with GAAP, consistently applied, in a form acceptable to Administrative Agent and certified by a Responsible Officer, together with a Compliance Certificate signed by a Responsible Officer in substantially the form of Exhibit C hereto;  as soon as available, but in any event within one hundred eighty (180) days after the end of Borrowers’ fiscal year, audited consolidated financial statements of Borrowers prepared in accordance with GAAP, consistently applied, together with an unqualified opinion on such financial statements of an independent certified public accounting firm reasonably acceptable to Administrative Agent;  as soon as available, but in any event no later than the earlier to occur of thirty (30) days following the beginning of each fiscal year or the date of approval by such Borrowers’ board of directors, an annual operating budget 

		 

and financial projections (including income statements, balance sheets and cash flow statements) for such fiscal year, presented in a monthly format, approved by Borrowers’ board of directors, and in a form and substance acceptable to Administrative Agent in its reasonable business judgment (each, a “Financial Plan”);  copies of all statements, reports and notices sent or made available generally by a Borrower to its security holders or to any holders of Subordinated Debt and, if applicable, all reports on Forms 10-K and 10-Q filed with the Securities and Exchange Commission within five (5) days after such filing; promptly upon receipt of notice thereof, a report of any legal actions pending or threatened against a Borrower or any Subsidiary that could reasonably be expected to result in damages or costs to a Borrower or any Subsidiary of Five Hundred Thousand Dollars ($500,000) or more; and  such budgets, sales projections, operating plans or other financial information as Administrative Agent may reasonably request from time to time.
		

		
			2)Exhibit C to the Loan and Security Agreement is hereby amended and restated in its entirety as set forth on Exhibit C attached hereto.
		

		
			3)Notwithstanding the provisions of Section 6.12 of the Loan and Security Agreement or the provisions of that certain Loan and Security Modification Agreement entered into as of March 5, 2019, Prescribe Wellness, LLC (“PW”) and Capstone Performance Systems, LLC, a Florida limited liability company (“Capstone Florida”), shall provide the Administrative Agent with a duly executed joinder to the Loan and Security Agreement and Guaranty and Indemnity Agreement, Security Deed Over Shares and General Security Deed and all other security documents required by Administrative Agent in connection therewith no later than January 3, 2020 (the “Joinder Date”); provided,  however, that such joinder shall not be required if PW and/or Capstone Florida merges with and into another Borrower upon written notice to the Administrative Agent in accordance with Section 7.3 of the Loan and Security Agreement prior to the Joinder Date.
		

		
			4)In accordance with Section 7.3 of the Loan and Security Agreement, notice is hereby provided to the Administrative Agent that Parent intends to (i) merge Capstone Florida with and into Capstone, with Capstone continuing as the surviving entity of such merger (the “Capstone FL Merger”), as soon as practicable after the date hereof and in any event prior to the Joinder Date; and (ii) following the effectiveness of the Capstone FL Merger, merge each of Robertson, Capstone,  TRHC, Mediture,  Cognify,  Careventions, TRSHC, SinfoniaRX,  Medliance,  eClusive,  DoseMe and PW with and into CareKinesis, with CareKinesis continuing as the surviving entity of such merger, in each case effective as of December 31, 2019. 
		

		
			CONSISTENT CHANGES.  The Existing Documents are each hereby amended wherever necessary to reflect the changes described above.
		

		
			NO DEFENSES OF THE BORROWERS/GENERAL RELEASE.  Each Borrower agrees that, as of this date, it has no defenses against the obligations to pay any amounts under the Existing Documents.  Each Borrower (each, a “Releasing Party”) acknowledges that the Lenders and the Administrative Agent would not enter into this Amendment without Releasing Party’s assurance that it has no claims against the Lenders and the Administrative Agent or any of the Lenders’ and the Administrative Agent’s officers, directors, employees or agents.  Except for the obligations arising hereafter under this Amendment, each Releasing Party releases the Lenders and the Administrative Agent, and each of the Lenders’ and the Administrative Agent’s officers, directors and employees from any known or unknown claims that Releasing Party now has against any Lender and/or the Administrative Agent of any nature, including any claims that Releasing Party, its successors, counsel, and advisors may in the future discover they would have now had if they had known facts not now known to them, whether founded in contract, in tort or pursuant to any other theory of liability, including but not limited to any claims arising out of or related to the Loan and Security Agreement or the transactions contemplated thereby.  Each Releasing Party waives the provisions of California Civil Code section 1542, which states:
		

		
			A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.
		

		
			

		 

		

		
			The provisions, waivers and releases set forth in this section are binding upon each Releasing Party and its shareholders, agents, employees, assigns and successors in interest.  The provisions, waivers and releases of this section shall inure to the benefit of the Lenders and the Administrative Agent and their respective agents, employees, officers, directors, assigns and successors in interest.  The provisions of this section shall survive payment in full of the Obligations, full performance of all the terms of this Amendment and the Loan and Security Agreement, and/or any Lender’s and/or the Administrative Agent’s actions to exercise any remedy available under the Loan and Security Agreement or otherwise.
		

		
			CONTINUING VALIDITY.  Each Borrower understands and agrees that in modifying the Existing Documents, the Lenders and the Administrative Agent are relying upon such Borrower’s representations, warranties, and agreements, as set forth in the Existing Documents.  Each Borrower represents and warrants that the representations and warranties contained in the Loan and Security Agreement are true and correct as of the date of this Amendment, and that no Event of Default has occurred and is continuing. Except as expressly modified pursuant to this Amendment, the terms of the Existing Documents remain unchanged and in full force and effect.  The Lenders’ and the Administrative Agent’s agreement to modifications to the Existing Documents pursuant to this Amendment in no way shall obligate any Lender and/or the Administrative Agent to make any future modifications to the Existing Documents.  Nothing in this Amendment shall constitute a satisfaction of the Obligations.  It is the intention of the Lenders, the Administrative Agent and the Borrowers to retain as liable parties all makers and endorsers of Existing Documents, unless the party is expressly released by the Lenders and the Administrative Agent in writing.  No maker, endorser, or guarantor will be released by virtue of this Amendment.  The terms of this paragraph apply not only to this Amendment, but also to any subsequent loan and security modification agreements.
		

		
			CONDITIONS PRECEDENT.  As a condition to the effectiveness of this Amendment, Bank shall have received, in form and substance satisfactory to Bank, the following:
		

		
			(a)payment of all Bank Expenses incurred through the date of this Amendment; and
		

		
			(b) such other documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate.
		

		
			NOTICE OF FINAL AGREEMENT.  BY SIGNING THIS DOCUMENT EACH PARTY REPRESENTS AND AGREES THAT:   THIS WRITTEN AGREEMENT REPRESENTS THE FINAL AGREEMENT BETWEEN THE PARTIES,  THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES, AND  THIS WRITTEN AGREEMENT MAY NOT BE CONTRADICTED BY EVIDENCE OF ANY PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OR UNDERSTANDINGS OF THE PARTIES.
		

		
			COUNTERSIGNATURE.  This Amendment shall become effective only when executed by the Lenders, the Administrative Agent and the Borrowers.
		

		
			[Signature Page Follows]
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

		
			IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first above written.
		

		
			BORROWERS:
		

		
			 
		

		
			TABULA RASA HEALTHCARE, INC.
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			CAREKINESIS, INC.
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			CAREVENTIONS, INC.
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			CAPSTONE PERFORMANCE SYSTEMS, LLC
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			J. A. ROBERTSON, INC.
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			MEDLIANCE LLC
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			 
		

		
			\
		

		
			 
		

		
			

		 

		

		
			CK SOLUTIONS, LLC
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			TRSHC HOLDINGS, LLC
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			SINFONIARX, INC.
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			TRHC MEC HOLDINGS, LLC
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			MEDITURE LLC
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			ECLUSIVE L.L.C.
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			COGNIFY, LLC
		

		
			 
		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			DOSEME, LLC
		

		
			 
		

		
			 
		

		
			

		 

		

		
			By:/s/ Brian W. Adams
		

		
			Name:Brian W. Adams
		

		
			Title:Chief Financial Officer
		

		
			 
		

		
			

		 

		

		
			IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first above written.
		

		
			ADMINISTRATIVE AGENT:
		

		
			 
		

		
			WESTERN ALLIANCE BANK, an Arizona corporation
		

		
			 
		

		
			By:/s/ Brian McCabe
		

		
			Name:Brian McCabe
		

		
			Title:Vice President 
		

		
			 
		

		
			 
		

		
			

		 

		

		
			IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed as of the date first above written.
		

		
			LENDERS:
		

		
			 
		

		
			WESTERN ALLIANCE BANK, an Arizona corporation
		

		
			 
		

		
			By:/s/ Brian McCabe
		

		
			Name:Brian McCabe
		

		
			Title:Vice President 
		

		
			
		

		
			

		 

		

		
			EXHIBIT C
COMPLIANCE CERTIFICATE
		

		
			TO:WESTERN ALLIANCE BANK, AS ADMINISTRATIVE AGENT
		

		
			FROM:TABULA RASA HEALTHCARE, INC., CAREKINESIS, INC., CAREVENTIONS, INC., CAPSTONE PERFORMANCE SYSTEMS, LLC, J. A. ROBERTSON, INC., MEDLIANCE LLC, CK SOLUTIONS, LLC, TRSHC HOLDINGS, LLC, SINFONIARX, INC., TRHC MEC HOLDINGS, LLC, MEDITURE LLC,  ECLUSIVE L.L.C., COGNIFY, LLC, and DOSEME, LLC
		

		
			The undersigned authorized officer of Tabula Rasa Healthcare, Inc., on behalf of itself and all other Borrowers, hereby certifies that in accordance with the terms and conditions of the Amended and Restated Loan and Security Agreement between Borrowers, Administrative Agent and the Lenders (the “Agreement”), (i) each Borrower is in complete compliance for the period ending ____________ with all required covenants except as noted below and (ii) all representations and warranties of Borrowers stated in the Agreement are true and correct as of the date hereof.  Attached herewith are the required documents supporting the above certification.  The Officer further certifies that these are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes.
		

		
			Please indicate compliance status by circling Yes/No under “Complies” column.
		

			
					
						Reporting Covenant

					
					
						Required

					
					
						 

					
					
						Complies

				
	
					
						A/R & A/P Agings

					
					
						Quarterly within 30 days

					
					
						 

					
					
						Yes

					
					
						No

				
	
					
						Deferred Revenue Report

					
					
						Quarterly within 30 days

					
					
						 

					
					
						Yes

					
					
						No

				
	
					
						Monthly financial statements

					
					
						Quarterly within 30 days

					
					
						 

					
					
						Yes

					
					
						No

				
	
					
						Compliance Certificate

					
					
						Quarterly within 30 days

					
					
						 

					
					
						Yes

					
					
						No

				
	
					
						Annual audited financial statements

					
					
						FYE within 180 days

					
					
						 

					
					
						Yes

					
					
						No

				
	
					
						Annual operating budget, sales projections and operating plans approved by board of directors

					
					
						Annually no later than 30 days after to the beginning of each fiscal year or Board approval

					
					
						Yes

					
					
						No

				
	
					
						A/R Audit

					
					
						Initial and Annually thereafter

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Deposit balances with Bank

					
					
						$

					
					
						 

					
					
						Yes

					
					
						No

				
	
					
						Deposit balance outside Bank

					
					
						$

					
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Financial Covenant

					
					
						Required

					
					
						Actual

					
					
						Complies

				
	
					
						Minimum Unrestricted Cash at Bank + Availability on Revolving Facility

					
					
						$3,000,000

					
					
						$

					
					
						Yes

					
					
						No

				
	
					
						Maximum Leverage (Quarterly commencing with month ending 12/31/2017)

					
					
						2.50:1.00

					
					
						_____:1.00

					
					
						Yes

					
					
						No

				
	
					
						Minimum Quarterly EBITDA (Quarterly commencing with month ending 12/31/2017)

					
					
						75%

					
					
						______%

					
					
						Yes

					
					
						No

				

		
			 
		

		
			
		

		

		 

	
					
						

					
						Comments Regarding Exceptions:  See Attached.

					
					
						 

					
					
						BANK USE ONLY

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						Sincerely,

					
					
						 

					
					
						Received by:

				
	
					
						 

					
					
						 

					
					
						AUTHORIZED SIGNER

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Date:

				
	
					
						SIGNATURE

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Verified:

				
	
					
						 

					
					
						 

					
					
						AUTHORIZED SIGNER

				
	
					
						TITLE

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Date:

				
	
					
						DATE

					
					
						 

					
					
						 

				
	
					
						 

					
					
						 

					
					
						Compliance
StatusYesNo

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]